SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
John Lok Man Law, Michael Logan, Michael Joyce, Abdolamir Landi, Darren Hockman, Kevin Crawford, Janelle Johnson, Gerald LaChance, Holly A. Saffran, Justin Shields, Eve Hobart, Raelynn Brassard, Elena Arutyunova, Kanti Pabbaraju, Matthew A. Croxen, Graham Tipples, M. Joanne Lemieux, D. Lorne Tyrrell, Michael Houghton
Topics & Concepts
VirologyNeutralizationAntibodyBiologyNeutralizing antibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Recombinant DNAImmunityPandemicCoronavirus disease 2019 (COVID-19)Immune systemImmunologyVirusMedicineInfectious disease (medical specialty)GeneticsGenePathologyDiseaseSARS-CoV-2 and COVID-19 ResearchBacillus and Francisella bacterial researchvaccines and immunoinformatics approaches